They found that reducing the RUNX1 protein by approximately 50% in the LSCs markedly abrogated their ability to engraft while RUNX1 knockdown abolished bulk cell survival and colony formation in primary human AML samples across diverse genetic groups. Here, RUNX1 is linked to acute myeloid leukemia.